1APLS / Apellis Pharmaceuticals, Inc. (BIT) - Forecast, Price Target, Estimates, Predictions

Apellis Pharmaceuticals, Inc.
IT ˙ BIT ˙ US03753U1060
€24.26 0.00 (0.00%)
2025-09-05
SHARE PRICE
Projected Stock Price
No data available.
Projected Revenue

No data available.
Projected Earnings Per Share

0.46 ↑237.23%

Estimated quarterly earnings by December 31, 2027.

Price Target
No data available.
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for Apellis Pharmaceuticals, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Why Are Analyst Ratings important?

In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.

Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.

If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?

You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.

How to Use Analyst Ratings ?

Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.

Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.

Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.

How are the Fintel Analyst Ratings different?

Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.

Date Analyst Prior Latest
Recommendation
Action
2025-05-09 Raymond James Strong Buy Outperform Downgrade
2025-05-09 B of A Securities Buy Neutral Downgrade
2025-05-14 Mizuho Neutral Neutral Maintains
2025-05-22 Citigroup Buy Buy Maintains
2025-07-16 B of A Securities Neutral Neutral Maintains
2025-04-29 Cantor Fitzgerald Overweight Initiate
2025-04-21 RBC Capital Sector Perform Sector Perform Maintains
2025-04-02 Scotiabank Sector Perform Sector Perform Maintains
2025-03-04 JP Morgan Overweight Overweight Maintains
2025-03-03 RBC Capital Sector Perform Sector Perform Maintains
2025-03-03 Goldman Sachs Neutral Neutral Maintains
2025-03-03 Wedbush Neutral Neutral Maintains
2025-03-03 HC Wainwright & Co. Buy Buy Reiterate
2025-02-13 HC Wainwright & Co. Buy Buy Reiterate
2025-01-29 RBC Capital Sector Perform Sector Perform Maintains
2025-01-21 RBC Capital Sector Perform Sector Perform Reiterate
2025-01-14 HC Wainwright & Co. Buy Buy Reiterate
2024-12-17 Goldman Sachs Buy Neutral Downgrade
2024-11-21 Morgan Stanley Equal-Weight Initiate
2024-11-07 Baird Outperform Outperform Maintains
2024-11-06 Wells Fargo Equal-Weight Equal-Weight Maintains
2024-11-06 Scotiabank Sector Perform Sector Perform Maintains
2024-11-06 RBC Capital Sector Perform Sector Perform Maintains
2024-11-06 Goldman Sachs Buy Buy Maintains
2024-11-06 Citigroup Buy Buy Maintains
2024-11-06 Oppenheimer Outperform Outperform Maintains
2024-11-06 Piper Sandler Neutral Neutral Maintains
2024-11-06 HC Wainwright & Co. Buy Buy Maintains
2024-11-06 B of A Securities Buy Buy Maintains
2024-11-06 Needham Buy Buy Maintains
2024-11-04 RBC Capital Sector Perform Sector Perform Reiterate
2024-10-24 Mizuho Neutral Neutral Maintains
2024-10-16 Scotiabank Sector Perform Initiate
2024-10-16 William Blair Outperform Initiate
2024-09-24 Wells Fargo Equal-Weight Equal-Weight Maintains
2024-09-23 Baird Outperform Outperform Maintains
2024-09-20 Needham Buy Buy Reiterate
2024-09-20 Mizuho Neutral Neutral Maintains
2024-09-13 JP Morgan Overweight Overweight Maintains
2024-08-13 JP Morgan Overweight Overweight Maintains
2024-08-09 UBS Buy Buy Maintains
2024-08-09 Wedbush Neutral Neutral Maintains
2024-08-09 Goldman Sachs Buy Buy Maintains
2024-08-09 Baird Outperform Outperform Maintains
2024-08-09 Needham Buy Buy Reiterate
2024-08-02 HC Wainwright & Co. Buy Buy Maintains
2024-08-02 Goldman Sachs Buy Buy Maintains
2024-08-02 Needham Buy Buy Reiterate
2024-07-31 Jefferies Buy Buy Maintains
2024-07-26 Baird Outperform Outperform Maintains
2024-07-23 Baird Outperform Outperform Maintains
2024-07-17 Goldman Sachs Buy Buy Maintains
2024-06-28 Baird Outperform Outperform Maintains
2024-05-31 Piper Sandler Neutral Initiate
2024-05-28 HC Wainwright & Co. Buy Buy Reiterate
2024-05-23 Wells Fargo Equal-Weight Equal-Weight Maintains
2024-05-08 HC Wainwright & Co. Buy Buy Reiterate
2024-05-08 Citigroup Buy Buy Maintains
2024-05-08 UBS Buy Buy Maintains
2024-05-08 Needham Buy Buy Reiterate
2024-04-29 Mizuho Neutral Neutral Maintains
2024-04-26 HC Wainwright & Co. Buy Buy Reiterate
2024-04-25 Needham Buy Buy Reiterate
2024-04-17 Wedbush Neutral Neutral Maintains
2024-04-15 HC Wainwright & Co. Buy Buy Reiterate
2024-04-09 Needham Buy Buy Reiterate
2024-03-27 Mizuho Neutral Neutral Maintains
2024-03-06 JP Morgan Overweight Overweight Maintains
2024-03-04 UBS Buy Buy Maintains
2024-02-28 HC Wainwright & Co. Buy Buy Reiterate
2024-02-28 Wedbush Neutral Neutral Maintains
2024-02-16 Mizuho Neutral Neutral Maintains
2024-02-06 Baird Outperform Outperform Reiterate
2024-02-05 Jefferies Hold Buy Upgrade
2024-01-30 Oppenheimer Outperform Outperform Maintains
2024-01-24 Needham Buy Buy Maintains
2024-01-17 Baird Outperform Outperform Maintains
2024-01-17 HC Wainwright & Co. Buy Buy Maintains
2024-01-12 Wedbush Neutral Neutral Maintains
2024-01-11 Raymond James Strong Buy Strong Buy Maintains
2024-01-09 Goldman Sachs Buy Buy Maintains
2023-12-15 Citigroup Buy Buy Maintains
2023-12-15 Oppenheimer Outperform Outperform Maintains
2023-12-15 Raymond James Strong Buy Strong Buy Maintains
2023-12-14 Wells Fargo Overweight Equal-Weight Downgrade
2023-12-14 Needham Buy Buy Maintains
2023-12-05 B of A Securities Neutral Buy Upgrade
2023-11-09 Goldman Sachs Buy Initiate
2023-11-02 Raymond James Strong Buy Strong Buy Maintains
2023-11-02 Mizuho Neutral Initiate
2023-11-01 Needham Buy Buy Maintains
2023-10-12 B of A Securities Neutral Neutral Maintains
2023-10-06 Citigroup Buy Buy Maintains
2023-10-06 JP Morgan Neutral Overweight Upgrade
2023-10-06 Raymond James Strong Buy Strong Buy Maintains
2023-09-26 HC Wainwright & Co. Buy Buy Reiterate
2023-09-20 HC Wainwright & Co. Buy Buy Reiterate
2023-09-15 Wells Fargo Equal-Weight Overweight Upgrade
2023-09-14 HC Wainwright & Co. Buy Buy Reiterate
2023-09-08 B of A Securities Neutral Neutral Maintains
2023-08-30 Citigroup Buy Buy Maintains
2023-08-30 Needham Buy Buy Reiterate
2023-08-29 Stifel Buy Buy Maintains
2023-08-24 Needham Buy Buy Reiterate
2023-08-23 Oppenheimer Outperform Outperform Reiterate
2023-08-23 Wedbush Neutral Neutral Reiterate
2023-08-23 UBS Buy Buy Maintains
2023-08-23 HC Wainwright & Co. Buy Buy Reiterate
2023-08-07 Wedbush Neutral Neutral Maintains
2023-08-07 HC Wainwright & Co. Buy Buy Reiterate
2023-08-03 JP Morgan Overweight Neutral Downgrade
2023-08-01 Baird Outperform Outperform Maintains
2023-08-01 B of A Securities Buy Neutral Downgrade
2023-08-01 HC Wainwright & Co. Buy Buy Reiterate
2023-08-01 Raymond James Strong Buy Strong Buy Maintains
2023-07-31 Needham Buy Buy Maintains
2023-07-31 HC Wainwright & Co. Buy Buy Reiterate
2023-07-21 Citigroup Buy Buy Maintains
2023-07-21 HC Wainwright & Co. Buy Buy Maintains
2023-07-20 Citigroup Buy Buy Maintains
2023-07-20 Wedbush Neutral Neutral Maintains
2023-07-20 Wells Fargo Equal-Weight Equal-Weight Maintains
2023-07-20 JP Morgan Overweight Overweight Maintains
2023-07-18 HC Wainwright & Co. Buy Buy Reiterate
2023-06-13 HC Wainwright & Co. Buy Buy Reiterate
2023-05-12 Oppenheimer Outperform Outperform Maintains
2023-05-08 Citigroup Buy Maintains
2023-05-05 Raymond James Strong Buy Maintains
2023-05-05 Credit Suisse Neutral Maintains
2023-05-05 Wells Fargo Equal-Weight Maintains
2023-05-05 HC Wainwright & Co. Buy Maintains
2023-05-05 Needham Buy Maintains
2023-04-20 HC Wainwright & Co. Buy Reiterate
2023-04-17 Wedbush Neutral Maintains
2023-04-14 Goldman Sachs Buy Maintains
2023-02-23 HC Wainwright & Co. Buy Reiterate
2023-02-22 Raymond James Strong Buy Maintains
2023-02-22 Needham Buy Maintains
2023-02-21 Stifel Buy Maintains
2023-02-21 Baird Outperform Maintains
2023-02-21 Citigroup Buy Maintains
2023-02-21 HC Wainwright & Co. Buy Reiterate
2023-02-21 Needham Buy Reiterate
2023-01-03 Wells Fargo Overweight Equal-Weight Downgrade
2022-11-15 JP Morgan Overweight Maintains
2022-11-10 Jefferies Buy Hold Downgrade
2022-11-08 Credit Suisse Neutral Maintains
2022-10-18 Raymond James Strong Buy Maintains
2022-09-12 Wedbush Neutral Maintains
2022-09-08 Stifel Buy Maintains
2022-08-18 Oppenheimer Outperform Maintains
2022-08-09 Credit Suisse Neutral Maintains
2022-08-09 Goldman Sachs Buy Maintains
2022-08-09 Raymond James Strong Buy Maintains
2022-07-20 Citigroup Buy Maintains
2022-07-19 HC Wainwright & Co. Buy Initiate
2022-05-24 Goldman Sachs Buy Maintains
2022-05-05 Credit Suisse Neutral Maintains
2022-05-05 Raymond James Strong Buy Maintains
2022-04-14 Roth Capital Neutral Sell Downgrade
2022-04-04 JP Morgan Overweight Maintains
2022-03-07 Goldman Sachs Buy Maintains
2022-03-01 Raymond James Strong Buy Maintains
2022-01-11 Raymond James Strong Buy Maintains
2021-12-08 Wells Fargo Overweight Initiate
2021-11-29 Roth Capital Buy Neutral Downgrade
2021-11-24 Citigroup Buy Maintains
2021-11-09 Raymond James Strong Buy Maintains
2021-09-10 Roth Capital Buy Maintains
2021-09-10 Credit Suisse Neutral Maintains
2021-09-10 Wedbush Outperform Neutral Downgrade
2021-09-10 BMO Capital Outperform Maintains
2021-09-10 Needham Buy Maintains
2021-08-19 Wedbush Neutral Outperform Upgrade
2021-08-19 Jefferies Buy Initiate
2021-08-10 Credit Suisse Neutral Maintains
2021-08-10 Raymond James Strong Buy Maintains
2021-07-08 BMO Capital Outperform Maintains
2021-07-02 JP Morgan Overweight Maintains
2021-06-28 Needham Buy Maintains
2021-05-21 UBS Buy Initiate
2021-04-29 Credit Suisse Neutral Maintains
2021-04-16 Goldman Sachs Buy Initiate
2021-02-26 Credit Suisse Neutral Maintains
2021-01-29 Credit Suisse Neutral Maintains
2021-01-08 Raymond James Strong Buy Maintains
2020-12-15 Roth Capital Buy Maintains
2020-11-23 Citigroup Buy Maintains
2020-11-19 Needham Buy Initiate
2020-09-01 Stifel Buy Initiate
2020-07-20 Roth Capital Buy Initiate
2020-06-30 Citigroup Buy Maintains
2020-06-17 BTIG Neutral Initiate
2020-06-08 JP Morgan Overweight Maintains
2020-04-28 Cantor Fitzgerald Overweight Maintains
2020-04-01 Raymond James Strong Buy Initiate
2020-03-31 BMO Capital Outperform Initiate
2020-03-11 Wedbush Underperform Neutral Upgrade
2020-03-02 Credit Suisse Neutral Maintains
2020-01-08 Oppenheimer Outperform Maintains
2020-01-07 Baird Overweight Maintains
2019-12-19 Bank of America Buy Initiate
2019-11-25 Cantor Fitzgerald Overweight Reiterate
2019-11-22 Wedbush Underperform Initiate
2019-11-05 Credit Suisse Neutral Initiate
2019-07-12 JP Morgan Neutral Overweight Upgrade
2019-07-09 Oppenheimer Outperform Initiate
2019-03-29 Baird Outperform Initiate
2019-01-23 JP Morgan Overweight Neutral Downgrade
2018-11-14 JP Morgan Overweight Overweight Maintains
2018-09-13 B. Riley FBR Buy Buy Maintains
2018-08-08 Cantor Fitzgerald Overweight Overweight Maintains
2018-07-30 B. Riley FBR Neutral Buy Upgrade
2018-07-10 Cowen & Co. Outperform Initiate
2018-05-24 Cantor Fitzgerald Overweight Initiate
2018-04-12 B. Riley FBR Buy Neutral Downgrade
2018-04-12 B. Riley Buy Neutral Downgrade
2018-03-23 JP Morgan Overweight Overweight Maintains
2018-02-08 B. Riley FBR Buy Initiate
2018-02-08 B. Riley Buy Initiate
2017-12-04 Citigroup Buy Initiate
2017-12-04 JP Morgan Overweight Initiate
2025-08-04 JP Morgan Overweight Overweight Maintains
2025-08-01 RBC Capital Sector Perform Sector Perform Maintains
2025-08-01 Citigroup Buy Buy Maintains
2025-05-08 RBC Capital Sector Perform Sector Perform Maintains
2025-05-08 Scotiabank Sector Perform Sector Perform Maintains
2025-05-08 Wells Fargo Equal-Weight Equal-Weight Maintains
2025-05-08 Baird Outperform Outperform Maintains
2025-05-07 Needham Buy Buy Maintains
2025-07-18 Baird Outperform Outperform Maintains
2025-07-02 Morgan Stanley Equal-Weight Equal-Weight Maintains
2025-06-02 Wells Fargo Equal-Weight Equal-Weight Maintains
2025-08-01 Cantor Fitzgerald Overweight Overweight Maintains
2025-08-01 Raymond James Outperform Outperform Maintains
2025-07-29 Citigroup Buy Buy Maintains
Revenue Estimates
No data available.
Earnings Estimates

The forecasted annual earnings of Apellis Pharmaceuticals, Inc. in 2032-12-31 is 5.05 per share.

One part of an analyst’s rating is a profit (i.e., earnings) estimate for the current quarter and/or future quarters. The measurement given is earnings per share (EPS). EPS is a metric that indicates how much a company earned as represented by one share of its stock over a specific period (typically three months).

Earnings per Share Calculation

To understand the earnings per share calculation, you must understand net income. Net income is the amount of money a company has left over after deducting appropriate expenses and taxes from its revenues).

The formula for earnings per share is net income divided by the total number of outstanding shares (i.e., available for purchase). For example:

Company A has a net income of $100 million and forty million outstanding shares. The EPS calculation is as follows:

100,000,000/40,000,000 = $2.50 per share

How to use Earnings Per Share in Stock Analysis

Earnings per share is an essential metric for you to consider when deciding to buy a stock. After all, a company with high earnings per share is productive and generates revenue in excess of its operating costs.

However, it’s not the only metric you should use. Metrics like price-to-earnings and debt-to-equity add additional perspective about a company’s health.

You should also be sure to compare a company’s EPS with a company in its sector. However, when you do, be aware that EPS is different and more important than net profit by itself. You may see a company that has a rising net profit. But if its outstanding shares are also rising, then its EPS might be flat or even edging lower.

Update Frequency: Quarterly

Date EPS Average (Quarterly) Number of Analysts (Quarterly) EPS Average (Annual) Number of Analysts (Annually)
2025-09-30 -0.29 15 -- --
2025-12-31 -0.23 13 -1.03 23
2026-03-31 -0.16 5 -- --
2026-06-30 -0.06 5 -- --
2026-09-30 0.04 5 -- --
2026-12-31 0.13 5 0.23 22
2027-03-31 -0.09 3 -- --
2027-06-30 0.21 3 -- --
2027-09-30 0.33 3 -- --
2027-12-31 0.46 3 1.48 21
2028-12-31 -- -- 2.22 8
2029-12-31 -- -- 3.44 7
2030-12-31 -- -- 4.28 7
2031-12-31 -- -- 4.67 7
2032-12-31 -- -- 5.05 7
EBITDA Estimates
No data available.
EBIT Estimates
No data available.
Other Listings
US:APLS $28.13
DE:1JK €23.90
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista